The current average analyst rating on the shares is buy and the breakdown of recommendations is 10 strong buy or buy, 3 hold and no sell or strong sell.
The average consensus recommendation for the biotechnology & medical research peer group is buy.
Wall Street's median 12-month price target for Arcus Biosciences, Inc. is $38.00, about 31.9% above its August 4 closing price of $28.80.
Cash position and 2026 outlook
Arcus ended Q2 with $775 million in cash and expects runway into 2028.
The company expects 2026 GAAP revenue between $65 million and $75 million.
Arcus expects to end 2026 with about $600 million in cash and anticipates cash runway until at least the second half of 2028.
R&D costs fell due to winding down late-stage and early-stage programs, offset by increased investment in casdatifan and the immunology pipeline.
G&A expenses declined due to streamlining initiatives across operations.
Q2 revenue falls on lower license income
U.S. biopharma firm's Q2 revenue fell sharply year over year due to prior one-time license revenue.
The company said the decline was mainly due to prior-year one-time license and development services revenue, partially offset by new access rights and collaboration income.
Arcus posted a Q2 net loss as research and development expenses outpaced revenue.
RCUS•
